Mesoblast's (ASX:MSB) Ryoncil is now available for purchase in the US, according to a Thursday filing with the Australian bourse.
Ryoncil is a US Food and Drug Administration-approved therapy for treating pediatric patients aged two months and above, including adolescents and teenagers, with steroid-refractory acute graft versus host disease or SR-aGvHD, per the filing.
Mesoblast's shares were up over 1% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.